Yokohama Japan, 24 May 2023
REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
REPROCELL’s subcontracting partner, Histocell, has established an authorized GMP ATMP manufacturing facility in Bilbao, Spain. Histocell has been providing GMP manufacturing services since 2008 and is highly experienced in manufacturing clinical MSC products including cell-free MSC-derived secretome and exosome cell therapies.
REPROCELL will market this new service globally by combining the skillset of its experienced commercial and project management team. The company’s experience in managing MSC-based phase II clinical trials in Japan will add great value for clients employing REPROCELL’s MSC manufacturing offering.
“REPROCELL’s commercial expertise will enhance the reach of Histocell’s rich/broad GMP ATMP production. The service will be a great addition to REPROCELL’s clinical stem cell offering.” said Chikafumi Yokoyama Ph.D., CEO of REPROCELL Inc.
“Histocell reinforces our production and marketing capacity for GMP manufacturing of ATMPs. We are delighted to have REPROCELL as a strategic partner in the stem cell field.” said Julio Font Ph.D., CEO of Histocell, S.L.